Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients

Abroad (travel likely)RecruitingPHASE2

Conditions

Cytomegalovirus Infections · Transplant-Related Disorder

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Penn Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Contact: Study coordinator (Kathryn Whitaker, MD) · katheryn.whitaker@pennmedicine.upenn.edu · 267-581-2135
Contact: Principal Investigator (Kathryn Whitaker, MD)
Contact: Principal Investigator (Emily A Blumberg, MD)
Emily Clausen, MD (Sub-investigator)
Juan Ortega-Legaspi, MD (Sub-investigator)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Immunoglobiulin-specific Prophylaxis of Citomegalovirus Infections in Immunocompromised Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Immunoglobulin Prophylaxis · Cytomegalovirus Infections · Allogeneic Hematopoietic Stem Cell Transplantation

Abroad (travel likely)Recruiting

Trieste, Italy

Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

Cytomegalovirus Infections · Kidney Transplant Infection · Pancreas Transplant

Abroad (travel likely)RecruitingPHASE3

Madison, United States

Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections

Cytomegalovirus Infection

Abroad (travel likely)RecruitingPHASE3

Paris, France · Paris, France

Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients

Cytomegalovirus Infections · Infection in Solid Organ Transplant Recipients · Neutropenia

Abroad (travel likely)RecruitingPHASE4

Boston, United States